By Marie Rosenthal, MS
In a unanimous vote, the FDA Antimicrobial Drugs Advisory Committee (AMDAC) endorsed the benefits over the risk of an experimental immunoprophylaxis for the prevention of respiratory syncytial virus lower respiratory tract disease (RSV LRTD) in newborns and infants during their first RSV season.
“My vote is yes, and it relates to four different factors. First, this is one of the most important infectious diseases resulting in significant illness in the pediatric